ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: treat-to-target

Results from Many Large Clinical Trials Remain Unpublished Years Later

Will Boggs MD  |  May 9, 2019

NEW YORK (Reuters Health)—Results from a substantial proportion of large, registered, randomized controlled trials (RCTs) can go unpublished for years after their completion, researchers report. “These unpublished and unreported trials include a vast number of patients, about 90,000,” Dr. John P. A. Ioannidis from Stanford University in California told Reuters Health. “Many people think that…

Filed under:Clinical Criteria/GuidelinesEducation & Training Tagged with:ClinicalTrials.govrandomized controlled trials (RCTs)unpublished clinical trial results

Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus

Lara C. Pullen, PhD  |  April 29, 2019

Although antimitochondrial antibodies are present in SLE patients, researchers have has difficulty investigating the phenomenon due to barriers in isolating pure mitochondria. The study describes a technique that allows for such an investigation and provides insight into how the adaptive immune system recognizes mitochondrial organelles…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:anti-mitochondrial antibodiessystemic lupus erythematosus (SLE)

The RISE Registry Delivers Practice-Based Evidence to Rheumatologists

Nancy A. Baker, ScD, MPH, OT; Margarita Fallena, MD; Tracy Johansson, MS; Janell Martin, CAE; Kaleb Michaud, PhD; Cynthia S. Crowson, PhD; Dina L. Jones, PT, PhD  |  April 15, 2019

The advent of quality-based healthcare, such as the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), requires rheumatology professionals to demonstrate their practice is based on interventions supported by the best available evidence and that their practice, in turn, provides quality care. These requirements have increased the need for methods to measure and quantify…

Filed under:Quality Assurance/ImprovementResearch Rheum Tagged with:practice-based researchQualified Clinical Data Registries (QCDRs)Rheumatology Informatics System for Effectiveness (RISE) Registry

MRI-Guided Therapy Offers No Improvement Over Conventional Treat to Target for RA

Lara C. Pullen, PhD  |  March 25, 2019

New research does not support the use of a magnetic resonance imaging (MRI)-guided strategy for treating RA patients. The study found that among RA patients in remission, an MRI-guided treat-to-target strategy compared with a conventional treat-to-target strategy did not result in improved disease activity remission rates or reduced radiographic progression…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Magnetic resonance imaging (MRI)MRIRheumatoid Arthritis (RA)

The RISE Registry: A Powerful Collaboration Tool for Clinicians & Researchers

Nancy A. Baker, SCD, MPH, OT; Margarita Fallena, MD; Tracy Johansson, MS; Janell Martin, CAE; Kaleb Michaud, PhD; Cynthia S. Crowson, PhD; Dina L. Jones, PT, PhD  |  March 21, 2019

Practice-based evidence, like that in the RISE registry, can be used to describe trends in patient care, look at comparative effectiveness of interventions and much more.

Filed under:Practice SupportResearch Rheum Tagged with:electronic health records (EHRs)practice-based evidencepractice-based researchRheumatology Informatics System for Effectiveness (RISE) RegistryRISE registry

Destructive Arthritis: From Prevention to Progression to Remission

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—Josef S. Smolen, MD, professor of internal medicine and chair of the Department of Rheumatology, Vienna General Hospital, Austria, presented the prestigious Paul Klemperer, MD, Memorial Lecture at the 2018 ACR/ARHP Annual Meeting. Dr. Smolen, whose work is frequently cited, created the treat-to-target strategy for rheumatoid arthritis (RA). Dr. Smolen began by noting a simple…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:2018 ACR/ARHP Annual MeetingTreat-to-Target

New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

Ruth Jessen Hickman, MD  |  March 18, 2019

Results of a recent study in Arthritis & Rheumatology fail to clarify whether urate-lowering therapies may potentially reduce mortality risk in patients with gout.1 The study also underscores the fact that many physicians are not following the ACR guideline to help their patients achieve target serum urate levels. Partly because of this, it remains unclear…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Allopurinolurate-lowering therapies

The Effects of Early RA Treatment on CVD

Carina Stanton  |  February 19, 2019

New research exploring the effects of etanercept on cardiovascular disease in treatment-naive, early RA patients suggests a treatment advantage with etanercept, a TNF inhibitor and methotrexate over treatment with methotrexate and a conventional synthetic disease-modifying anti-rheumatic drug…

Filed under:ConditionsRheumatoid Arthritis Tagged with:biologic DMARDsconventional DMARDs (csDMARDS)Disease-modifying antirheumatic drugs (DMARDs)early RAetanerceptRheumatoid Arthritis (RA)

The 2018 ARHP Merit Awards & ACR Distinguished Fellows

Carol Patton, with Keri Losavio  |  December 18, 2018

CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARHP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find interviews…

Filed under:AwardsMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)Daniel SchafferDanielle RiceDr. Ann Marie SzymanskiDr. Antonia ValenzuelaDr. April M. JorgeDr. Bella MehtaDr. Brittany AdlerDr. Carol A. OatisDr. Charles G. HelmickDr. Christina H. OpavaDr. DeAnna A. Baker FrostDr. Debbie Ehrmann-FeldmanDr. Marcela A. FerradaDr. Patrick R. WoodDr. Sara AlehashemiDr. Shudan WangHiral MasterJanalee TaylorLisa Robbins

AFLAR Experts Discuss Highlights, Hurdles in Rheumatology in Africa

Thomas R. Collins  |  December 18, 2018

CHICAGO—Rheumatology physicians and researchers from Africa said the field’s resources and medical literature on the continent are slowly expanding, but they repeatedly lamented that the millions who suffer from rheumatic diseases there have major obstacles to overcome to access care. Their reviews and assessments—sometimes grim and sometimes hopeful—came in a session that was a joint…

Filed under:ConditionsGout and Crystalline ArthritisMeeting ReportsWorkforce Tagged with:2018 ACR/ARHP Annual MeetingAFLARGoutHIVPediatric Rheumatologyrheumatologist shortageworkforce shortage

  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 18
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences